{"id":"adjuvant-chemotherapy","safety":{"commonSideEffects":[{"rate":"20-80","effect":"Neutropenia"},{"rate":"10-50","effect":"Anemia"},{"rate":"5-40","effect":"Thrombocytopenia"},{"rate":"30-90","effect":"Nausea and vomiting"},{"rate":"20-90","effect":"Alopecia"},{"rate":"10-40","effect":"Mucositis"},{"rate":"30-80","effect":"Fatigue"},{"rate":"10-50","effect":"Diarrhea"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Secondary malignancy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adjuvant chemotherapy is a treatment strategy rather than a single drug, involving the use of chemotherapeutic agents (such as alkylating agents, antimetabolites, or topoisomerase inhibitors) given after surgery or radiation to target micrometastatic disease. The goal is to improve overall survival and disease-free survival by destroying cancer cells that may have escaped the primary tumor but are not yet clinically detectable.","oneSentence":"Adjuvant chemotherapy uses cytotoxic drugs administered after primary cancer treatment to eliminate residual cancer cells and reduce recurrence risk.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:26:45.924Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of various solid tumors (breast cancer, colorectal cancer, gastric cancer, ovarian cancer, and others depending on regimen)"},{"name":"Post-operative or post-radiation therapy to reduce recurrence risk"}]},"trialDetails":[{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma","enrollment":692},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT07496190","phase":"PHASE2","title":"Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-01","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":59},{"nctId":"NCT02676349","phase":"PHASE2","title":"Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)","status":"COMPLETED","sponsor":"Institut de Cancérologie de Lorraine","startDate":"2016-10-13","conditions":"Pancreatic Carcinoma","enrollment":130},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT04503694","phase":"PHASE2","title":"Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2021-03-25","conditions":"Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":72},{"nctId":"NCT07498140","phase":"NA","title":"Procedural Framing and Epidural Steroid Injection Outcomes","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2026-03-25","conditions":"Lumbosacral Radiculopathy","enrollment":210},{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT00512304","phase":"PHASE2","title":"Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2007-08","conditions":"Gastric Cancer","enrollment":63},{"nctId":"NCT02595944","phase":"PHASE3","title":"Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-22","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7","enrollment":903},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":188},{"nctId":"NCT07219316","phase":"NA","title":"Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision","status":"COMPLETED","sponsor":"Adichunchanagiri Institute of Medical Sciences, B G Nagara","startDate":"2025-10-15","conditions":"Breast-Conserving Surgery","enrollment":40},{"nctId":"NCT02954874","phase":"PHASE3","title":"Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-18","conditions":"Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7","enrollment":1155},{"nctId":"NCT01272037","phase":"PHASE3","title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-28","conditions":"Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma","enrollment":5018},{"nctId":"NCT06312137","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-03","conditions":"Non Small Cell Lung Cancer","enrollment":780},{"nctId":"NCT05001880","phase":"PHASE2","title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-22","conditions":"Peritoneal Malignant Mesothelioma","enrollment":66},{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":"Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":1210},{"nctId":"NCT07487662","phase":"PHASE2","title":"TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-18","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":105},{"nctId":"NCT04574856","phase":"PHASE2","title":"Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-11-04","conditions":"Glioblastoma","enrollment":30},{"nctId":"NCT04432207","phase":"PHASE1","title":"A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Imugene Limited","startDate":"2020-11-30","conditions":"Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV","enrollment":24},{"nctId":"NCT07493421","phase":"NA","title":"To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.","status":"RECRUITING","sponsor":"Unidade Local de Saúde São João","startDate":"2026-03-01","conditions":"Pancreatic Adenocarcinoma, Peritoneal (Metastatic) Cancer","enrollment":20},{"nctId":"NCT07492615","phase":"PHASE2","title":"A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-29","conditions":"Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":276},{"nctId":"NCT06850103","phase":"PHASE2","title":"SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-04-22","conditions":"Colorectal Carcinoma, Oligometastases, pMMR","enrollment":51},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT07106632","phase":"PHASE3","title":"Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-04-01","conditions":"Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer","enrollment":3380},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT07260175","phase":"PHASE2","title":"Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-11-18","conditions":"Cholangiocarcinoma, IDH Mutation","enrollment":40},{"nctId":"NCT04266249","phase":"PHASE2","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-03-13","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8","enrollment":2175},{"nctId":"NCT07489066","phase":"PHASE2","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-01","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC)","enrollment":120},{"nctId":"NCT01030250","phase":"","title":"Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2009-06-11","conditions":"Breast Cancer","enrollment":238},{"nctId":"NCT06915025","phase":"PHASE3","title":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2025-07-09","conditions":"Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer","enrollment":500},{"nctId":"NCT07125755","phase":"PHASE3","title":"Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-15","conditions":"Squamous Cell Cancer of Head and Neck (SCCHN)","enrollment":386},{"nctId":"NCT07486687","phase":"PHASE3","title":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2026-04","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer","enrollment":1000},{"nctId":"NCT07279935","phase":"PHASE4","title":"Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-05-31","conditions":"Non-small Cell Lung Cancer","enrollment":100},{"nctId":"NCT04415944","phase":"PHASE2","title":"Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05-20","conditions":"Ovarian Epithelial Cancer Stage I, Ovarian Epithelial Cancer Stage II, Ovarian Epithelial Cancer Stage III","enrollment":10},{"nctId":"NCT04559139","phase":"PHASE2, PHASE3","title":"Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Stage II Gallbladder Cancer AJCC v8, Stage IIA Gallbladder Cancer AJCC v8, Stage IIB Gallbladder Cancer AJCC v8","enrollment":186},{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT06181201","phase":"","title":"Association Between the Composition of the Intestinal Microbiota and Tumor Response in Locally Advanced Rectal Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2024-02-19","conditions":"Cancer of Rectum","enrollment":2},{"nctId":"NCT07479628","phase":"PHASE2","title":"Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2026-04-01","conditions":"Thymic Carcinoma","enrollment":31},{"nctId":"NCT06931717","phase":"PHASE3","title":"A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy","status":"RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2026-01-12","conditions":"Non-Small Cell Lung Cancer","enrollment":390},{"nctId":"NCT04016142","phase":"PHASE2","title":"Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2020-07-15","conditions":"Locally Advanced Cancer, Cervical Cancer","enrollment":21},{"nctId":"NCT00959556","phase":"","title":"Study of Blood Samples in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2007-11-28","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT07478900","phase":"NA","title":"Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2025-09-10","conditions":"Breast Cancer (Locally Advanced or Metastatic), Tattoo Skin Markers, Neoadjuvant Chemoimmunotherapy","enrollment":30},{"nctId":"NCT02871167","phase":"NA","title":"Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2016-12","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT02818920","phase":"PHASE2","title":"Neoadjuvant Pembrolizumab","status":"COMPLETED","sponsor":"Neal Ready MD PhD","startDate":"2017-01","conditions":"Non-small Cell Lung Carcinoma","enrollment":35},{"nctId":"NCT06141031","phase":"PHASE1","title":"Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-01-16","conditions":"Pancreatic Cancer","enrollment":5},{"nctId":"NCT07459296","phase":"PHASE3","title":"Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC","status":"RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-03-05","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":266},{"nctId":"NCT07472803","phase":"","title":"Longitudinal Body Composition Assessment in Breast Cancer Patients","status":"RECRUITING","sponsor":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","startDate":"2025-05-19","conditions":"Breast Neoplasms, Body Composition, Sarcopenia","enrollment":100},{"nctId":"NCT07474324","phase":"PHASE2","title":"Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-15","conditions":"GC/GEJC","enrollment":124},{"nctId":"NCT06284317","phase":"PHASE3","title":"A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.","status":"RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2025-01-15","conditions":"Non Small Cell Lung Cancer","enrollment":290},{"nctId":"NCT06133517","phase":"PHASE2","title":"PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para el Progreso de la Oncología en Cantabria","startDate":"2025-01-20","conditions":"Urothelial Bladder Carcinoma","enrollment":70},{"nctId":"NCT03842982","phase":"PHASE3","title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-05-03","conditions":"Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma","enrollment":362},{"nctId":"NCT07472478","phase":"PHASE2","title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2026-03-15","conditions":"Lung Cancer (NSCLC), KRAS G12C Lung Cancer","enrollment":32},{"nctId":"NCT07237256","phase":"PHASE3","title":"Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-12-18","conditions":"Breast Cancer","enrollment":3902},{"nctId":"NCT06654622","phase":"","title":"Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2023-04-01","conditions":"Colo-rectal Cancer, Colorectal Cancer Recurrent","enrollment":175},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT00904410","phase":"PHASE4","title":"Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2005-05","conditions":"Breast Cancer","enrollment":63},{"nctId":"NCT03732677","phase":"PHASE3","title":"Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-16","conditions":"Muscle Invasive Bladder Cancer","enrollment":1063},{"nctId":"NCT01614704","phase":"","title":"Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2011-10","conditions":"Breast Cancer, Fertility","enrollment":135},{"nctId":"NCT02515110","phase":"NA","title":"Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2015-08-04","conditions":"Breast Cancer, Node-positive Breast Cancer, Breast Adenocarcinoma","enrollment":137},{"nctId":"NCT00421096","phase":"PHASE2","title":"Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer","status":"TERMINATED","sponsor":"Centre Oscar Lambret","startDate":"2005-05","conditions":"Uterine Cervical Cancer","enrollment":19},{"nctId":"NCT07379918","phase":"","title":"Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-06-28","conditions":"Breast Cancer (Early Breast Cancer), Breast Cancer Survivors, Breast Cancer Prognostic","enrollment":1000},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT00911911","phase":"NA","title":"Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2007-02-22","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT03875716","phase":"NA","title":"Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-05-20","conditions":"Head and Neck Cancer","enrollment":111},{"nctId":"NCT01480869","phase":"PHASE3","title":"Study of Vitamin D Supplementation Tailored to Vitamin D Deficiency in Breast Cancer Patients","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2011-07","conditions":"Breast Cancer","enrollment":215},{"nctId":"NCT03249389","phase":"NA","title":"Assessing the Changes in Markers of Calcium Vitamin Metabolism of for Breast Cancer Adjuvant (CALCIOBS)","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2015-10","conditions":"Breast Cancer","enrollment":146},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT05763199","phase":"PHASE2","title":"Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2023-08-01","conditions":"Ovarian Epithelial Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma","enrollment":20},{"nctId":"NCT04472910","phase":"NA","title":"GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-21","conditions":"Resectable Pancreatic Cancer","enrollment":84},{"nctId":"NCT05819892","phase":"PHASE1","title":"Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-07-17","conditions":"Endometrial Cancer","enrollment":21},{"nctId":"NCT04832854","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-04-23","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":50},{"nctId":"NCT05061550","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-04-14","conditions":"Non-small Cell Lung Cancer","enrollment":630},{"nctId":"NCT01918527","phase":"PHASE3","title":"Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vejle Hospital","startDate":"2013-09","conditions":"Colon Cancer","enrollment":250},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT07076186","phase":"PHASE2","title":"Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-02","conditions":"Uterine Leiomyosarcoma","enrollment":48},{"nctId":"NCT05733689","phase":"PHASE1","title":"Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-06-27","conditions":"Gastroesophageal Adenocarcinoma","enrollment":20},{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT03619083","phase":"","title":"Assessment of Sensory Gating, Attention, and Executive Control in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-13","conditions":"Breast Cancer","enrollment":187},{"nctId":"NCT07209189","phase":"PHASE2","title":"Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-04","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer","enrollment":75},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT07120282","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-28","conditions":"Lung Cancer (NSCLC)","enrollment":108},{"nctId":"NCT05343013","phase":"PHASE2","title":"TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-06-06","conditions":"Colorectal Cancer","enrollment":25},{"nctId":"NCT05871099","phase":"PHASE3","title":"Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not","status":"RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2022-11-20","conditions":"Gastric Cancer","enrollment":616},{"nctId":"NCT02047474","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-03-25","conditions":"Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer","enrollment":46},{"nctId":"NCT06430866","phase":"PHASE3","title":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)","status":"RECRUITING","sponsor":"Amgen","startDate":"2024-09-12","conditions":"Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)","enrollment":154},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT04302025","phase":"PHASE2","title":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2020-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":99},{"nctId":"NCT01616875","phase":"PHASE2","title":"Bristol Bladder Trial","status":"COMPLETED","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","startDate":"2012-07-25","conditions":"Infiltrating Bladder Urothelial Carcinoma","enrollment":28},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT05247684","phase":"PHASE2","title":"AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-02-20","conditions":"Resectable Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT05052671","phase":"","title":"ctDNA Assay in Patients With Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2022-05-25","conditions":"Pancreas Cancer","enrollment":50},{"nctId":"NCT07136493","phase":"NA","title":"Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer","status":"SUSPENDED","sponsor":"City of Hope Medical Center","startDate":"2026-05-12","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":350},{"nctId":"NCT06109779","phase":"PHASE3","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-04","conditions":"Biliary Tract Cancer","enrollment":757},{"nctId":"NCT03313778","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2017-08-14","conditions":"Solid Tumors","enrollment":161},{"nctId":"NCT05526755","phase":"PHASE2","title":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-06","conditions":"Stage II-IIIB Non-small Cell Lung Carcinoma","enrollment":188},{"nctId":"NCT03386617","phase":"PHASE2","title":"AKY15-HK-301_NEPA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2018-02-27","conditions":"Breast Cancer","enrollment":55}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ALTERED STATE OF CONSCIOUSNESS"},{"count":1,"reaction":"ANASTOMOTIC COMPLICATION"},{"count":1,"reaction":"ATAXIA"},{"count":1,"reaction":"DISORIENTATION"},{"count":1,"reaction":"DYSARTHRIA"},{"count":1,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":1,"reaction":"HALLUCINATION"},{"count":1,"reaction":"INADEQUATE ANALGESIA"},{"count":1,"reaction":"INCOHERENT"},{"count":1,"reaction":"MIOSIS"}],"_approvalHistory":[],"publicationCount":35989,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["XEOLX*6 courses","Carboplatin","Paclitaxel","mFOLFOX6","according to local/ national guidelines"],"phase":"marketed","status":"active","brandName":"Adjuvant chemotherapy","genericName":"Adjuvant chemotherapy","companyName":"Institut de Cancérologie de Lorraine","companyId":"institut-de-canc-rologie-de-lorraine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adjuvant chemotherapy uses cytotoxic drugs administered after primary cancer treatment to eliminate residual cancer cells and reduce recurrence risk. Used for Adjuvant treatment of various solid tumors (breast cancer, colorectal cancer, gastric cancer, ovarian cancer, and others depending on regimen), Post-operative or post-radiation therapy to reduce recurrence risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":33,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}